The present invention relates generally to improved formulations of 6-thioguanine (6-TG), their methods of preparation, and their use in treatment methods. The invention provides a pharmaceutical composition including 6-TG, and a polyethylene oxide polymer having a molecular weight of between about 900,000 g/mol and about 9,000,000 g/mol, their methods of preparation, and their use in methods for treating a disease or condition of the distal intestine that responds to 6-TG, wherein the 6-TG is released in the distal intestine.
Described is a rectal suppository. The rectal suppository comprises 6-thioguanine, at least one hard fat, and at least one surfactant. Further or alternatively, the rectal suppository comprises about 1 to 9 mg of 6-thioguanine. Further or alternatively, there is described a method of preventing, treating and/or managing inflammatory bowel disease in a subject. The method comprises administering a rectal suppository to the subject in need thereof. Further or alternatively, there is described a method of manufacturing a rectal suppository. The method comprises the steps of (a) heating a hard fat to become a liquid hard fat, (b) adding at least one surfactant to the liquid hard fat, (c) adding 6-thioguanine to the liquid hard fat, (d) forming the hard fat into a rectal suppository. Step (b) is optionally carried out before step (c) or after step (c).
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
3.
PHARMACEUTICAL RECTAL SUPPOSITORY COMPOSITIONS OF 6-THIOGUANINE, METHODS OF TREATMENT AND/OR METHODS OF MANUFACTURING
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Surman, Peter William
Shi, Zhen
Binnie, Fergus Cameron
Ritchie, Christopher
Long, Yuefeng
Abrégé
Described is a rectal suppository. The rectal suppository comprises 6-thioguanine, at least one hard fat, and at least one surfactant. Further or alternatively, the rectal suppository comprises about 1 to 9 mg of 6-thioguanine. Further or alternatively, there is described a method of preventing, treating and/or managing inflammatory bowel disease in a subject. The method comprises administering a rectal suppository to the subject in need thereof. Further or alternatively, there is described a method of manufacturing a rectal suppository. The method comprises the steps of (a) heating a hard fat to become a liquid hard fat, (b) adding at least one surfactant to the liquid hard fat, (c) adding 6-thioguanine to the liquid hard fat, (d) forming the hard fat into a rectal suppository. Step (b) is optionally carried out before step (c) or after step (c).
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations in relation to women's health;
dietary supplements in relation to women's health;
nutritional supplements in relation to women's health;
dietary or nutritional supplements for humans in relation to
women's health; vitamins in relation to women's health;
vitamin supplements in relation to women's health;
nutritional drinks for dietary purposes in relation to
women's health; liquid vitamin supplements in relation to
women's health; health supplements in relation to women's
health.
The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Arranging, conducting or providing in-person or online
educational services in relation to women's health featuring
the provision of individual or collective training,
coaching, classes, workshops, seminars, webinars, providing
online educational classes via a live video chat or via live
chat; providing information or instruction in the field of
women's health; providing manuals or teaching materials in
the field of women's health; conducting classes, publication
or online publication of electronic books, magazines,
educational documents, educational materials, educational
text, journals or diaries [blog services] in relation to
women's health; publishing e-books in relation to women's
health in electronic form on the internet; production of
video podcasts in relation to women's health; providing
entertainment via video podcasts in relation to women's
health; providing non-downloadable videos on inspirational
or motivational topics for women via a web site in relation
to women's health; podcast entertainment in relation to
women's health; production of podcasts in relation to
women's health; providing entertainment via podcasts in
relation to women's health; conducting classes, virtual
classes or online classes in relation to exercise and
nutrition for women in the field of women's health.
9.
LOPINAVIR AND RITONAVIR FOR THE TREATMENT OF CERVIX DISORDERS
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Hampson, Ian
Hampson, Lynne
Abrégé
The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The compositions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1.
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Surman, Peter, William
Shi, Zhen
Hsi, Shih-Liang
Abrégé
Described is a pharmaceutical composition in capsule form. The capsule comprises capsule fill. The capsule fill comprises a therapeutically effective amount of an active agent selected from the group consisting of tretinoin, pharmaceutically acceptable salts thereof, and combinations thereof, at least one carrier, optionally at least one viscosity modifier, optionally at least one chelating agent, optionally at least one antioxidant.
The present invention relates generally to improved formulations of 6- thioguanine (6-TG), their methods of preparation, and their use in treatment methods. The invention provides a pharmaceutical composition comprising 6-TG, and a polyethylene oxide polymer having a molecular weight of between about 900,000 g/mol and about 9,000,000 g/mol, their methods of preparation, and their use in methods for treating a disease or condition of the distal intestine that responds to 6-TG, wherein the 6-TG is released in the distal intestine.
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Binnie, Fergus
Surman, Peter
Abrégé
The present invention relates to self-emulsifying pharmaceutical compositions comprising an unsaturated free fatty acid, at least two emulsifiers and at least one active pharmaceutical ingredient; to the use of said pharmaceutical compositions as a medicament; and to processes for the preparation of said compositions.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Hampson, Ian
Hampson, Lynne
Binnie, Fergus Cameron
Surman, Peter
Abrégé
Provided herein are methods and compositions for treating and/or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and/or inhibiting the progression of HSV related conditions.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment- resistant depression and treatment-resistant anxiety.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Cosmetic preparations; Cosmetic creams; Cosmetic products for skin care, namely, skin lotions, skin cleansers, skin softeners, skin masks, skin toners, skin moisturizers, skin conditioners, skin soaps, non-medicated skin serums; Herbal extracts for cosmetic purposes Coaching in the field of cosmetics, health, and wellbeing; education services, namely, providing classes and instruction in the field of cosmetics, health, and wellbeing; training in the field of cosmetics, health, and wellbeing; on-line publication of journals; diaries blog services, namely, online journals being blogs featuring blog posts related to cosmetics, health, and wellbeing; providing online non-downloadable electronic publications in the nature of brochures in the field of cosmetics, health, and wellbeing; online publication of electronic books; online publication of electronic journals; online publication of electronic magazines; providing non-downloadable instructional videos via a website in the field of cosmetics, health, and wellbeing; arranging of educational courses in the field of cosmetics; publication of educational materials, namely, articles; production of educational and instructional materials, namely, online non-downloadable electronic publications in the nature of blog posts featuring educational materials in the field of cosmetics, health, and wellbeing; lifestyle counselling, namely, counseling services in the field of lifestyle wellness; personal fitness training; all of the aforementioned services including but not limited to the provision of such services electronically, by means of computers, computer networks or the Internet including via online
The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
Douglas Pharmaceuticals Limited (Nouvelle‑Zélande)
Inventeur(s)
Hampson, Ian
Hampson, Lynne
Abrégé
The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The com-positions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1.
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Binnie, Fergus
Surman, Peter
Abrégé
The present invention relates to self-emulsifying pharmaceutical compositions comprising an unsaturated free fatty acid, at least two emulsifiers and at least one active pharmaceutical ingredient; to the use of said pharmaceutical compositions as a medicament; and to processes for the preparation of said compositions.
The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Hampson, Ian
Hampson, Lynne
Binnie, Fergus Cameron
Surman, Peter
Abrégé
Provided herein are methods and compositions for treating and/or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir, methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and/or inhibiting the progression of HSV related conditions.
The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; food and dietary supplements
including vitamins and vitamin preparations and extracts,
mineral and mineral supplements, herbal supplements, and
nutritional supplements.
The present invention relates to anhydrous pharmaceutical compositions for topical application comprising at least one active pharmaceutical ingredient and a hydrophilic muco-adhesive agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
The present invention relates to semi-solid pharmaceutical compositions comprising an unsaturated free fatty acid, a stiffening agent and at least one active pharmaceutical ingredient; to the use of said pharmaceutical compositions as a medicament; and to processes for the preparation of said compositions.
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Hampson, Ian
Hampson, Lynne
Abrégé
The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The compositions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1.
The present invention concerns pharmaceutical compositions formulated for dermal application comprising a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir: ritonavir is between 9:1 and 18:1. Such compositions are useful for treating, or preventing, skin cancers and premalignant dermal conditions.
The invention provides an oral extended release formulation for the treatment of treatment- resistant depression, treatment-resistant anxiety, and phobia.
C07C 225/20 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du squelette carboné
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
DOUGLAS PHARMACEUTICALS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Abell, Andrew David
Coxon, James Morriss
Jones, Matthew Alan
Mcnabb, Stephen Brian
Neffe, Axel Thomas
Aitken, Steven Geoffrey
Stuart, Blair Gibb
Nikkel, Janna Marie
Duncan, Joanna Kimberley
Klanchantra, Mutita
Morton, James David
Bickerstaffe, Roy
Robertson, Lucinda Jane Goodricke
Lee, Hannah Yun Young
Muir, Matthew Stewart
Abrégé
The present invention provides a novel class of macrocyclic compounds, which are useful as cysteine protease inhibitors. Also provided are novel intermediates and methods of preparing the compounds. The invention also provides pharmaceutical compositions comprising the compounds. The compounds and compositions are useful in methods of treating or preventing one or more diseases associated with cysteine protease activity, particularly those associated with calpain activity.
The present invention is directed to methods and compositions for topical administration of acitretin. More specifically, the present invention is related to methods and compositions for the treatment or prevention or reduction of symptoms or signs of dermatological conditions using acitretin in a topical administration. More specifically, the present invention is related to methods and compositions containing acitretin which are effective for the treatment or prevention or reduction of symptoms or signs of keratoses, in particular actinic keratosis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; food and dietary supplements including vitamins and vitamin preparations and extracts, mineral and mineral supplements, herbal supplements, and nutritional supplements.
